JP5746137B2 - アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 - Google Patents
アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 Download PDFInfo
- Publication number
- JP5746137B2 JP5746137B2 JP2012501126A JP2012501126A JP5746137B2 JP 5746137 B2 JP5746137 B2 JP 5746137B2 JP 2012501126 A JP2012501126 A JP 2012501126A JP 2012501126 A JP2012501126 A JP 2012501126A JP 5746137 B2 JP5746137 B2 JP 5746137B2
- Authority
- JP
- Japan
- Prior art keywords
- arginase
- peg
- bacillus
- cys
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16386309P | 2009-03-26 | 2009-03-26 | |
| US61/163,863 | 2009-03-26 | ||
| PCT/CN2010/071357 WO2010124547A1 (en) | 2009-03-26 | 2010-03-26 | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521201A JP2012521201A (ja) | 2012-09-13 |
| JP2012521201A5 JP2012521201A5 (enExample) | 2013-05-09 |
| JP5746137B2 true JP5746137B2 (ja) | 2015-07-08 |
Family
ID=42784510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501126A Active JP5746137B2 (ja) | 2009-03-26 | 2010-03-26 | アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8507245B2 (enExample) |
| EP (1) | EP2411040B1 (enExample) |
| JP (1) | JP5746137B2 (enExample) |
| CN (1) | CN102481345B (enExample) |
| AU (1) | AU2010242422B2 (enExample) |
| CA (1) | CA2756442C (enExample) |
| WO (1) | WO2010124547A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382525B2 (en) * | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| CA2766039A1 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| JP6063378B2 (ja) | 2010-01-26 | 2017-01-18 | バンヤン・バイオマーカーズ・インコーポレイテッド | アルギニノコハク酸合成酵素に関係する組成物および方法 |
| EP2654776B1 (en) * | 2010-12-21 | 2018-11-21 | Bio-Cancer Treatment International Ltd. | Use of pegylated recombinant human arginase for treatment of leukemia |
| CN103184209B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| US8877183B2 (en) | 2012-06-26 | 2014-11-04 | National Institutes Of Health (Nih) | Methods for treatment of ocular diseases |
| US9011845B2 (en) | 2012-06-26 | 2015-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for treatment of inflammatory and infectious viral diseases |
| EP3137103B1 (en) | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| CN105112391B (zh) * | 2015-09-22 | 2018-07-06 | 浙江道尔生物科技有限公司 | 一种人源精氨酸酶突变体及其制备方法和用途 |
| CN106692961B (zh) * | 2015-11-17 | 2020-12-11 | 长春市福迪奥美科技有限公司 | 精氨酸酶组合物、精氨酸酶激活剂及其应用 |
| CN106434710A (zh) * | 2016-10-14 | 2017-02-22 | 江南大学 | 一种耐热精氨酸酶的基因表达序列和应用 |
| CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
| TWI922426B (zh) * | 2017-08-16 | 2026-04-21 | 香港商鎧耀波麗堂（香港）有限公司 | 用於胺基酸耗竭治療之組合物的用途 |
| TWI878212B (zh) | 2017-12-05 | 2025-04-01 | 瑞典商伊梅爾迪卡製藥公司 | 用於治療精胺酸酶1缺乏症之方法及組合物 |
| CN112513099A (zh) | 2018-05-31 | 2021-03-16 | 香港理工大学 | 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用 |
| WO2020081994A1 (en) | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| CN109793917B (zh) * | 2019-02-11 | 2020-10-09 | 海南建科药业有限公司 | 一种预防结直肠手术后吻合口瘘的凝胶的制备方法 |
| BR112022003633A2 (pt) | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| EP4069280A4 (en) * | 2019-12-02 | 2024-01-03 | The Hong Kong Polytechnic University | METHOD FOR INDUCING INTERMITTENT FASTING AND MODULATING AUTOPHAGY |
| US20230181694A1 (en) * | 2020-05-14 | 2023-06-15 | Kyon Biotech Ag | Treatment of respiratory viral infections |
| WO2022063178A1 (en) * | 2020-09-23 | 2022-03-31 | The Hong Kong Polytechnic University | Fluorescent biosensor for rapid determination of l-arginine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| WO2003063780A2 (en) * | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| RU2335539C2 (ru) | 2002-06-20 | 2008-10-10 | Байо-Кэнсер Тритмент Интернэшнл Лимитид | Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| CA2497794A1 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| WO2006058486A1 (en) | 2004-12-03 | 2006-06-08 | Bio-Cancer Treatment International Limited | Use of arginase in combination with 5fu and other compounds for treatment of human malignancies |
| CA2766039A1 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
-
2010
- 2010-03-26 AU AU2010242422A patent/AU2010242422B2/en active Active
- 2010-03-26 US US12/732,188 patent/US8507245B2/en active Active
- 2010-03-26 CN CN201080023256.4A patent/CN102481345B/zh active Active
- 2010-03-26 CA CA2756442A patent/CA2756442C/en active Active
- 2010-03-26 EP EP10769236.0A patent/EP2411040B1/en active Active
- 2010-03-26 WO PCT/CN2010/071357 patent/WO2010124547A1/en not_active Ceased
- 2010-03-26 JP JP2012501126A patent/JP5746137B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102481345B (zh) | 2015-04-22 |
| JP2012521201A (ja) | 2012-09-13 |
| AU2010242422B2 (en) | 2014-12-04 |
| US8507245B2 (en) | 2013-08-13 |
| AU2010242422A1 (en) | 2011-10-27 |
| WO2010124547A1 (en) | 2010-11-04 |
| CA2756442C (en) | 2016-03-29 |
| EP2411040A4 (en) | 2012-09-12 |
| US20100247508A1 (en) | 2010-09-30 |
| CN102481345A (zh) | 2012-05-30 |
| EP2411040B1 (en) | 2015-09-23 |
| EP2411040A1 (en) | 2012-02-01 |
| CA2756442A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8507245B2 (en) | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents | |
| US9382525B2 (en) | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents | |
| KR102442231B1 (ko) | 종양 치료를 위한 키누레닌 고갈 효소의 투여 | |
| EP2964761B1 (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment | |
| JP2024069234A (ja) | アスパラギナーゼを用いた治療法 | |
| ES2987380T3 (es) | Administración de enzimas de depleción de la quinurenina para la terapia tumoral | |
| CN105531371A (zh) | 用于治疗目的的工程改造的灵长类动物l-甲硫氨酸酶 | |
| WO2013097657A1 (zh) | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 | |
| TWI827593B (zh) | 人類犬尿胺酸酶及其用途 | |
| KR20190026813A (ko) | 시스틴의 인간-효소 매개된 고갈 | |
| AU2008286742A1 (en) | Protein-polymer conjugates | |
| EP2721057B1 (en) | Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer | |
| EP2196477B1 (en) | Modified recombinant human endostatin and its application | |
| US20260022367A1 (en) | Broad spectrum nanozymes | |
| CN102724980B (zh) | 蛋白-聚合物偶联物的治疗用途 | |
| EA020347B1 (ru) | Пептид-полимерные конъюгаты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150409 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5746137 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |